US5218704A
(en)
*
|
1989-10-30 |
1993-06-08 |
Texas Instruments |
Real-time power conservation for portable computers
|
ATE410518T1
(de)
*
|
1994-03-23 |
2008-10-15 |
Univ Ohio |
Kompaktnukleinsäure und ihre verabreichung in zellen
|
US6008202A
(en)
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
*
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
US5994316A
(en)
*
|
1996-02-21 |
1999-11-30 |
The Immune Response Corporation |
Method of preparing polynucleotide-carrier complexes for delivery to cells
|
US6258792B1
(en)
|
1996-04-12 |
2001-07-10 |
University Of Pittsburgh |
Cationic cholesteryl derivatives containing cyclic polar groups
|
DK0904282T3
(da)
|
1996-04-12 |
2002-03-04 |
Univ Pittsburgh |
Hidtil ukendte kationiske cholesterylderivater indeholdende cykliske polære grupper
|
AU727447B2
(en)
*
|
1996-07-03 |
2000-12-14 |
University Of Pittsburgh |
Emulsion formulations for hydrophilic active agents
|
CA2268417A1
(en)
*
|
1996-10-09 |
1998-04-16 |
Oxford Biomedica (Uk) Limited |
Mononuclear phagocytes in therapeutic drug delivery
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US7097829B2
(en)
*
|
1996-11-21 |
2006-08-29 |
Cedars-Sinai Medical Center |
Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
|
US6913926B2
(en)
*
|
1996-11-21 |
2005-07-05 |
Cedars-Sinai Medical Center |
Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
|
US6894031B1
(en)
*
|
1996-11-21 |
2005-05-17 |
Cedars-Sinai Medical Center |
Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
AU2868099A
(en)
|
1998-02-13 |
1999-08-30 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
DE19858005B4
(de)
*
|
1998-12-16 |
2007-02-08 |
november Aktiengesellschaft, Gesellschaft für Molekulare Medizin |
Synthetisches Nucleinsäure-Partikel
|
AU4188100A
(en)
*
|
1999-04-08 |
2000-11-14 |
Gregory M. Glenn |
Dry formulation for transcutaneous immunization
|
US6281005B1
(en)
*
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
EP1268555A2
(de)
*
|
2000-03-27 |
2003-01-02 |
The Regents of The University of California |
Gerichtete liganden gegen die nicht-sekrethorische komponente, und nicht-stengelregion von pigr und methoden zu deren verwendung
|
US20020042388A1
(en)
|
2001-05-01 |
2002-04-11 |
Cooper Mark J. |
Lyophilizable and enhanced compacted nucleic acids
|
CA2410265A1
(en)
*
|
2000-05-31 |
2001-12-06 |
Copernicus Therapeutics, Inc. |
Lyophilizable and enhanced compacted nucleic acids
|
GB0027328D0
(en)
*
|
2000-06-23 |
2000-12-27 |
Aventis Pharma Inc |
Bioengineered vehicles for targeted nucleic acid delivery
|
EP1330516B1
(de)
*
|
2000-11-03 |
2007-01-17 |
The Regents Of The University Of Michigan |
Oberflächentransfektion und expressionsverfahren
|
US20020081736A1
(en)
*
|
2000-11-03 |
2002-06-27 |
Conroy Susan E. |
Nucleic acid delivery
|
US6812217B2
(en)
|
2000-12-04 |
2004-11-02 |
Medtronic, Inc. |
Medical device and methods of use
|
DE10063112A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Bayer Ag |
Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
|
US7527802B2
(en)
*
|
2001-02-13 |
2009-05-05 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccine for transcutaneous immunization
|
WO2002075306A1
(en)
*
|
2001-03-16 |
2002-09-26 |
Large Scale Biology Corporation |
Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications
|
US7294511B2
(en)
*
|
2001-03-22 |
2007-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
JP2004535388A
(ja)
*
|
2001-04-30 |
2004-11-25 |
ターゲティッド ジェネティクス コーポレイション |
脂質含有薬物送達複合体およびそれらの生成方法
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
US6909030B2
(en)
*
|
2001-10-15 |
2005-06-21 |
Cedars-Sinai Medical Center |
PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
|
US20040014698A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
US20040016013A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
|
US20040014704A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent induces tolerance
|
RU2377253C2
(ru)
*
|
2002-12-02 |
2009-12-27 |
Амген Фремонт,Инк. |
Антитела, специфичные к фактору некроза опухолей, и их применение
|
JP2006517790A
(ja)
*
|
2003-01-09 |
2006-08-03 |
インヴィトロジェン コーポレーション |
ポリペプチド−核酸複合体の細胞の送達および活性化
|
US7824709B2
(en)
|
2003-02-14 |
2010-11-02 |
Children's Hospital And Research Center At Oakland |
Lipophilic drug delivery vehicle and methods of use thereof
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
US20050208032A1
(en)
*
|
2004-01-16 |
2005-09-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
US7358223B2
(en)
|
2004-10-04 |
2008-04-15 |
Nitto Denko Corporation |
Biodegradable cationic polymers
|
EP2287303B1
(de)
|
2004-11-12 |
2014-07-02 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
|
US20100272769A1
(en)
*
|
2005-08-03 |
2010-10-28 |
Amcol International |
Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
|
US20080184618A1
(en)
*
|
2005-08-03 |
2008-08-07 |
Amcol International |
Virus-Interacting Layered Phyllosilicates and Methods of Use
|
US20070031512A1
(en)
*
|
2005-08-03 |
2007-02-08 |
Amcol International Corporation |
Virus-interacting layered phyllosilicates and methods of inactivating viruses
|
US7700541B2
(en)
|
2006-04-06 |
2010-04-20 |
Nitto Denko Corporation |
Biodegradable cationic polymers
|
PT2056882E
(pt)
|
2006-08-01 |
2012-11-19 |
Univ Texas |
Identificação de um micro-rna que ativa a expressão da cadeia pesada de beta-miosina
|
JP2010512313A
(ja)
|
2006-12-06 |
2010-04-22 |
メディミューン,エルエルシー |
全身性エリテマトーデスの治療方法
|
US9260476B2
(en)
|
2007-02-23 |
2016-02-16 |
The Research Foundation For The State University Of New York |
RNA targeting compounds and methods for making and using same
|
AU2008218939B2
(en)
*
|
2007-02-23 |
2014-05-08 |
The Research Foundation Of State University Of New York |
RNA targeting compounds and methods for making and using same
|
WO2008137066A1
(en)
*
|
2007-05-02 |
2008-11-13 |
The Board Of Regents Of The University Of Oklahoma |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
EP2068924A4
(de)
|
2007-05-03 |
2011-07-20 |
Medimmune Llc |
Interferon-alpha-induzierte pharmakodynamische marker
|
KR101510778B1
(ko)
|
2007-07-12 |
2015-04-10 |
상가모 바이오사이언스 인코포레이티드 |
알파 1,6 당전이효소(fut8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물
|
KR101706259B1
(ko)
|
2007-07-31 |
2017-02-14 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
섬유증을 조절하는 마이크로-rna 집단 및 이의 용도
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
US8051513B2
(en)
*
|
2007-12-31 |
2011-11-08 |
Monster Medic, Inc. |
Ambulance cot system
|
CN102036689B
(zh)
|
2008-03-17 |
2014-08-06 |
得克萨斯***大学董事会 |
神经肌肉突触维持和再生中涉及的微小rna的鉴定
|
CA2726768C
(en)
|
2008-06-10 |
2016-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
WO2009158678A1
(en)
|
2008-06-27 |
2009-12-30 |
Children's Hospital & Research Center At Oakland |
Lipophilic nucleic acid delivery vehicle and methods of use therefor
|
CA2734235C
(en)
|
2008-08-22 |
2019-03-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
EP3156494B8
(de)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genomänderung bei ratten mithilfe von zink-finger-nukleasen
|
EP2379720B1
(de)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Durch den promoter mir-21 angetriebene gezielte krebstherapie
|
CA2934285C
(en)
|
2009-02-04 |
2018-11-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
AU2010235161B2
(en)
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
NZ619527A
(en)
|
2009-04-14 |
2015-06-26 |
Nestec Sa |
Inflammatory bowel disease prognostics
|
CA2769262C
(en)
|
2009-07-28 |
2019-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
WO2011060098A1
(en)
|
2009-11-10 |
2011-05-19 |
Prometheus Laboratories Inc. |
Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
|
EP2526112B1
(de)
|
2010-01-22 |
2018-10-17 |
Dow AgroSciences LLC |
Gezielte genommodifikation
|
EP2660318A1
(de)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Gezielte Genommodifikation mit partiell einzelsträngigen Donatormolekülen
|
WO2011108930A1
(en)
|
2010-03-04 |
2011-09-09 |
Interna Technologies Bv |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
WO2012005572A1
(en)
|
2010-07-06 |
2012-01-12 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
MX2013005346A
(es)
*
|
2010-11-15 |
2013-07-03 |
Avon Prod Inc |
Cosmeticos biofuncionales anclados para uso prolongado.
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
WO2013016446A2
(en)
|
2011-07-25 |
2013-01-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
KR102061557B1
(ko)
|
2011-09-21 |
2020-01-03 |
상가모 테라퓨틱스, 인코포레이티드 |
이식 유전자 발현의 조절을 위한 방법 및 조성물
|
EP2769321B1
(de)
|
2011-10-21 |
2016-06-01 |
Nestec S.A. |
Verfahren zur verbesserung der diagnose einer entzündlichen darmerkrankung
|
ES2886147T3
(es)
|
2011-12-22 |
2021-12-16 |
Interna Tech B V |
MiARN para el tratamiento del cáncer de cabeza y de cuello
|
WO2013130824A1
(en)
|
2012-02-29 |
2013-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
US9486540B2
(en)
|
2012-03-09 |
2016-11-08 |
Northeastern University |
Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
|
US10883119B2
(en)
|
2012-07-11 |
2021-01-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for delivery of biologics
|
EP3444342B1
(de)
|
2012-07-11 |
2020-05-27 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von lysosomalen speicherkrankheiten
|
UA118957C2
(uk)
|
2012-08-29 |
2019-04-10 |
Сангамо Біосайєнсиз, Інк. |
Спосіб і композиція для лікування генетичного захворювання
|
CA2886684C
(en)
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
EP2928303A4
(de)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
Faktor-viii-mutationsreparatur und toleranzinduktion
|
CA2896070A1
(en)
|
2012-12-21 |
2014-06-26 |
The Trustees Of Columbia University In The City Of New York |
Biomarkers for chronic traumatic encephalopathy
|
US8980864B2
(en)
*
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2014151551A1
(en)
|
2013-03-15 |
2014-09-25 |
Baylor Research Institute |
Ulcerative colitis (uc)-associated colorectal neoplasia markers
|
US9873894B2
(en)
|
2013-05-15 |
2018-01-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
CA2917569A1
(en)
|
2013-07-11 |
2015-01-15 |
The Trustees Of Columbia University In The City Of New York |
Micrornas that silence tau expression
|
AU2014312295C1
(en)
|
2013-08-28 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
DK3441468T3
(da)
|
2013-10-17 |
2021-07-26 |
Sangamo Therapeutics Inc |
Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation
|
CN105934524A
(zh)
|
2013-11-11 |
2016-09-07 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿氏病的方法和组合物
|
EP3492593B1
(de)
|
2013-11-13 |
2021-08-18 |
Children's Medical Center Corporation |
Nukleasevermittelte regulierung der genexpression
|
EP3068783B1
(de)
|
2013-11-15 |
2020-09-23 |
The Board of Trustees of the Leland Stanford Junior University |
Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
CA2931637C
(en)
|
2013-12-09 |
2023-10-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating hemophilia
|
HUE051232T2
(hu)
|
2014-02-03 |
2021-03-01 |
Sangamo Therapeutics Inc |
Béta-talasszémia kezelésére szolgáló eljárások és készítmények
|
CA2942762C
(en)
|
2014-03-18 |
2023-10-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
RU2691102C2
(ru)
|
2014-05-08 |
2019-06-11 |
Сангамо Байосайенсиз, Инк. |
Способы и композиции для лечения болезни хантингтона
|
HUE055583T2
(hu)
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
|
US20180094243A1
(en)
|
2015-04-03 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
US10450585B2
(en)
|
2015-07-13 |
2019-10-22 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
JP7409773B2
(ja)
|
2015-07-31 |
2024-01-09 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
改変された細胞および治療の方法
|
US10435441B2
(en)
|
2015-09-23 |
2019-10-08 |
Sangamo Therapeutics, Inc. |
HTT repressors and uses thereof
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
CA3010738A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
AU2016391970B2
(en)
|
2016-02-02 |
2024-02-22 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
JP7033583B2
(ja)
|
2016-07-13 |
2022-03-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を高めるための方法、組成物及びキット
|
SG10201913948PA
(en)
|
2016-08-24 |
2020-03-30 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
MY193234A
(en)
|
2016-08-24 |
2022-09-27 |
Sangamo Therapeutics Inc |
Regulation of gene expression using engineered nucleases
|
EP3528852A4
(de)
|
2016-10-20 |
2020-06-03 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von morbus fabry
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
WO2018102665A1
(en)
|
2016-12-01 |
2018-06-07 |
Sangamo Therapeutics, Inc. |
Tau modulators and methods and compositions for delivery thereof
|
EP4276187A3
(de)
|
2016-12-08 |
2024-01-17 |
Case Western Reserve University |
Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
|
WO2018119060A1
(en)
|
2016-12-20 |
2018-06-28 |
Bristol-Myers Squibb Company |
Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
|
AU2018256877B2
(en)
|
2017-04-28 |
2022-06-02 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
JP7025537B2
(ja)
|
2017-10-03 |
2022-02-24 |
アプタヘム アクチエボラグ |
抗炎症および抗凝固および器官保護特性を有する核酸分子
|
EP3704250A1
(de)
|
2017-11-03 |
2020-09-09 |
InteRNA Technologies B.V. |
Mirna-molekül, äquivalent, antagomir oder quelle davon zur behandlung und/oder diagnose eines zustands und/oder einer erkrankung im zusammenhang mit neuronaler defizienz oder neuronaler (re)generation
|
IL276082B2
(en)
|
2018-01-17 |
2024-01-01 |
Vertex Pharma |
DNA-PK inhibitor compounds, preparations containing them and their uses
|
AU2019209293B2
(en)
|
2018-01-17 |
2023-07-27 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
US20200361877A1
(en)
|
2018-01-17 |
2020-11-19 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
JP2021525058A
(ja)
*
|
2018-04-09 |
2021-09-24 |
チェックメイト ファーマシューティカルズ |
ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
|
CN113015741A
(zh)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
程序性细胞死亡1(pd1)特异性核酸酶
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
US20200270618A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
AU2019360270A1
(en)
|
2018-10-18 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX.
|
US20200268906A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
CA3116918A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|
CN113748126A
(zh)
|
2018-11-30 |
2021-12-03 |
因提玛生物科学公司 |
鉴定免疫调节基因的方法
|
CN113474328A
(zh)
|
2019-01-11 |
2021-10-01 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
US11866469B2
(en)
|
2019-02-06 |
2024-01-09 |
Klogenix Llc |
DNA binding proteins and uses thereof
|
US20220154157A1
(en)
|
2019-02-06 |
2022-05-19 |
Emendobio Inc. |
New engineered high fidelity cas9
|
US20200316116A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Method for the treatment of beta-thalassemia
|
US20220202957A1
(en)
|
2019-04-09 |
2022-06-30 |
The Regents Of The University Of California |
Long-lasting analgesia via targeted in vivo epigenetic repression
|
US20210317192A9
(en)
|
2019-05-29 |
2021-10-14 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
JP7284473B2
(ja)
*
|
2019-06-24 |
2023-05-31 |
学校法人東京理科大学 |
血液成分分離方法及びマイクロ流体デバイスの目詰まり防止剤
|
AU2020376048A1
(en)
|
2019-11-01 |
2022-06-02 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
CN115715203A
(zh)
|
2020-05-06 |
2023-02-24 |
塞勒克提斯公司 |
对细胞进行基因修饰以递送治疗性蛋白质的方法
|
CA3177093A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
EP4182297A1
(de)
|
2020-07-16 |
2023-05-24 |
Acuitas Therapeutics, Inc. |
Kationische lipide zur verwendung in lipidnanopartikeln
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
EP4341300A1
(de)
|
2021-05-21 |
2024-03-27 |
Cellectis S.A. |
Erhöhung der wirksamkeit von t-zell-vermittelter immuntherapie durch modulation von krebsassoziierten fibroblasten in soliden tumoren
|
WO2023070072A1
(en)
|
2021-10-21 |
2023-04-27 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Retroelement-generated transcription factor decoys
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
WO2023196725A1
(en)
|
2022-04-07 |
2023-10-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Continuous multiplexed phage genome engineering using a retron editing template
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|